A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It
Key Points
The transactions involved 795 shares sold for an estimated total value of about $216,000.
The disposition reduced Michael Burkes Brophy's direct equity holdings by 2%.
The activity was non-discretionary, executed to satisfy tax withholding obligations associated with the vesting of restricted stock units under a Rule 10b5-1 plan.
- 10 stocks we like better than Natera ›
Michael Burkes Brophy, the chief financial officer of Natera, Inc. (NASDAQ:NTRA), sold 795 shares of common stock at $271.74 per share in transactions executed on August 3 and August 4, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (directly held) | 795 |
| Transaction value | ~$216,000 |
| Post-transaction shares (directly held) | 51,637 |
| Post-transaction value | $14.21 million |
Transaction value based on SEC Form 4 weighted average sale price ($271.74); post-transaction value based on the August 4 market close ($275.19).
Key questions
- Was this a discretionary market transaction?
No. The sale was a non-discretionary "sell-to-cover" transaction to meet tax obligations following the vesting of equity awards. The trades were carried out under a Rule 10b5-1 trading plan that was originally adopted on June 9, 2025, and modified on September 10, 2025. - What is the insider's current ownership profile?
Brophy holds 51,637 shares directly, representing a 0.04% ownership stake in the company. This equity position is valued at $14.21 million based on the market close of $275.19 on August 4. - How has the stock performed leading up to this disclosure?
As of the August 4 transaction date, Natera has delivered a one-year total return of 102%. The company currently carries a market capitalization of $39.4 billion. - What are the company's recent financial fundamentals?
Austin-based Natera, a diagnostics firm focused on molecular testing services such as the Panorama non-invasive prenatal test, reported trailing 12-month revenue of $2.7 billion and a net loss of $192.3 million.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-04) | $275.19 |
| Market Capitalization | $39.4 billion |
| Revenue (TTM) | $2.7 billion |
| Net Income (TTM) | -$192.3 million |
Company Snapshot
- Natera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama for non-invasive prenatal testing, Vistara for single-gene disorder screening, and Horizon for carrier screening, generating revenue through test orders from healthcare providers and patients globally.
- The company operates a laboratory-based diagnostics business model, generating revenue by performing proprietary molecular tests and providing clinical insights to support reproductive health, oncology, and organ transplant management decisions.
- Natera's primary customers include obstetricians, maternal-fetal medicine specialists, genetic counselors, and healthcare systems, with target markets encompassing pregnant women, cancer patients, and transplant recipients seeking advanced diagnostic information.
Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the reproductive health and oncology diagnostics markets. The company's competitive advantage derives from its proprietary testing platforms and expanding clinical applications across multiple therapeutic areas. With a presence in Austin, Natera continues to scale its operations to capture growing demand for non-invasive and precision diagnostic solutions.
What this transaction means for investors
Brophy sold on Monday and Tuesday, just before Natera reported earnings on Thursday (after the market closed) and right at the edge of the window that typically closes ahead of results. That timing, plus the tiny size, points to exactly what the filing says it is, tax withheld on vesting shares under a preset plan, not a finance chief front-running his own report. He kept 51,637 shares worth better than $14 million, so nothing here dents his stake.
The report that followed his sales was a strong one. Natera grew second-quarter revenue about 38% to $753 million, well past expectations, powered by its Signatera cancer-detection test, and raised full-year guidance by $100 million. That guidance is Brophy's own, and he framed it cautiously, telling investors it "assumes stable Signatera pricing" through the rest of the year, leaving room for upside if prices keep climbing.
Signatera's average selling price sat near $1,275 last quarter against a long-term target of roughly $2,000, so the single biggest lever on Natera's growth is a price that still has far to run, and that’s even more good news for long-term investors.
Should you buy stock in Natera right now?
Before you buy stock in Natera, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Natera wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 10, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.
Recommended Articles
